Quest Diagnostics (DGX) Stock Forecast & Price Target

$163.43 +0.96 (+0.59%)

Closing price 02/4/2025 03:59 PM Eastern

Extended Trading

$163.37 -0.06 (-0.04%)

As of 02/4/2025 06:06 PM Eastern

Quest Diagnostics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
6

Buy
9

Based on 15 Wall Street analysts who have issued ratings for Quest Diagnostics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 6 have given a hold rating, 7 have given a buy rating, and 2 have given a strong buy rating for DGX.

Consensus Price Target

$177.69
8.72% Upside

According to the 15 analysts' twelve-month price targets for Quest Diagnostics, the average price target is $177.69. The highest price target for DGX is $185.00, while the lowest price target for DGX is $165.00. The average price target represents a forecasted upside of 8.72% from the current price of $163.43.

Get the Latest News and Ratings for DGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Quest Diagnostics and its competitors.

DGX Analyst Ratings Over Time

Type	Current Forecast 2/6/24 to 2/5/25	1 Month Ago 1/7/24 to 1/6/25	3 Months Ago 11/8/23 to 11/7/24	1 Year Ago 2/6/23 to 2/6/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$177.69	$172.15	$164.58	$146.10
Forecasted Upside	8.72% Upside	12.96% Upside	5.37% Upside	15.71% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

DGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Quest Diagnostics Stock vs. The Competition

Type	Quest Diagnostics	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	8.72% Upside	15,482.54% Upside	13.00% Upside
News Sentiment Rating	Positive News See Recent DGX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/4/2025	JPMorgan Chase & Co. 3 of 5 stars	Lisa Gill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$173.00 ➝ $180.00	+9.61%
2/3/2025	Mizuho 3 of 5 stars	Ann Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$177.00 ➝ $178.00	+9.56%
2/3/2025	UBS Group 4 of 5 stars	Kevin Caliendo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$166.00 ➝ $170.00	+5.01%
2/3/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$165.00 ➝ $180.00	+11.76%
1/31/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$172.00 ➝ $182.00	+11.17%
1/31/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephanie Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$168.00 ➝ $175.00	+6.73%
1/6/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
1/6/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$169.00 ➝ $174.00	+14.53%
12/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$145.00 ➝ $172.00	+12.65%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$179.00 ➝ $182.00	+16.56%
Get the Latest News and Ratings for DGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.
12/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$175.00 ➝ $185.00	+16.97%
10/23/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
10/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$165.00 ➝ $185.00	+17.48%
10/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$157.00 ➝ $182.00	+15.58%
8/28/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	In-Line	$165.00	+7.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:47 AM ET.

DGX Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Quest Diagnostics is $177.69, with a high forecast of $185.00 and a low forecast of $165.00.
: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 6 hold ratings, 7 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DGX shares.
: According to analysts, Quest Diagnostics's stock has a predicted upside of 8.72% based on their 12-month stock forecasts.
: Over the previous 90 days, Quest Diagnostics's stock had 3 upgrades by analysts.
: Quest Diagnostics has been rated by research analysts at Bank of America, Barclays, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Piper Sandler, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Quest Diagnostics less than other "medical" companies. The consensus rating score for Quest Diagnostics is 2.73 while the average consensus rating score for "medical" companies is 2.82. Learn more on how DGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:DGX) was last updated on 2/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Stock Forecast & Price Target